Neural Therapeutics Inc. · CSE:NURL
Neural Therapeutics — Investor Presentation (June 2024)
25 slides from Neural Therapeutics's investor presentation, June 2024
Slide 1: Neural Therapeutics Inc. Corporate Presentation
Neural Therapeutics Inc. Corporate Presentation June 2024
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements CONFIDENTIAL INFORMATION NOT AN OFFER This presentation (the “Presentation"), inclusive of all materials and information provided herewith This Presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any s
Slide 3: Disclaimer and Forward-Looking Statements (cont.)
Disclaimer and Forward-Looking Statements (cont.) FORWARD LOOKING STATEMENT AND RISK FACTORS Certain statements contained in this Presentation relate to the historical experience of our founders, management team This Presentation includes certain “forward-looking information” and “forward-looking st
Slide 4: 2024 Will Be a Breakthrough Year for Psychedelic Investments
2024 Will Be a Breakthrough Year for Psychedelic Investments 2023 • May: AMA announces new billing codes for psychedelic therapies • June: FDA issues first draft guidance on clinical trials with psychedelic drugs • July: Australia permits therapeutic use of MDMA & Psilocybin • Thanks to our Scientif
Slide 5: Executive Overview
Executive Overview Neural Therapeutics is a life sciences company focused on drug development from psychoactive plants • Our first target is mescaline from the San Pedro cactus (Echinopsis pachanoi or Trichocereus pachanoi) • Peer-reviewed and historical scientific literature indicates that plant-ba
Slide 6: Market Stats - Pharmaceutical
Market Stats - Pharmaceutical $70+ billion total market Institutional Market Momentum ADHD: $29.6 Billion Smoking Cessation: $23.4 Billion Depression*: $12.1 Billion Substance Abuse Treatment*: $16.5 Billion • Veterans of War & Heroic Hearts Project: non-profits that connect military veterans strugg
Slide 7: Mescaline: A Potential Game-Changer in Therapeutics
Mescaline: A Potential Game-Changer in Therapeutics Effective in Treating Mental Health Conditions • Mescaline shows promise as a treatment option for challenging mental health conditions Conditions Addressed • Effective in managing complex mental ailments Evidence of Treating Comorbidities • E.g. P
Slide 8: Advantages: Plant-Derived Mescaline
Advantages: Plant-Derived Mescaline Mescaline Fights Addiction • Plant-based mescaline shows strong promise in breaking the cycle of addiction by rewiring the brain* Enhanced Healing – Accelerated Neural Plasticity • Full spectrum psychedelics boost brain repair, potentially offering better mental r
Slide 9: Our Goal: Revolutionizing Treatment for Substance Use Disorders with Mescaline
Our Goal: Revolutionizing Treatment for Substance Use Disorders with Mescaline Innovative Thesis: Advancing non-hallucinogenic neural plasticity—transforming substance use treatments. Breakthrough: Pioneering sub-hallucinogenic mescaline to boost neural adaptation, eliminating psychedelic effects. I
Slide 10: R&D Targeted Near-Term Objectives – Pharmaceutical and Nutraceutical
R&D Targeted Near-Term Objectives – Pharmaceutical and Nutraceutical Supply Chain: Expect to have cGMP supply chain agreement complying with US FDA standards by Q4 Partners: CROs selection by Q3, formulation and pre-clinical studies targeting submission to US FDA SOPs: Refine patent-pending extracti
Slide 11: Research & Development Pathway
Research & Development Pathway Pharmaceutical Development • Pre-Clinical Studies: Create a formulation(s) that can be tested in IND- enabling studies Supply Chain Permits and Studies • Clinical Studies: Conduct Phase I – III clinical trials (after regulatory approval) Optimizing Extraction Gov. Perm
Slide 12: Key Milestones
Key Milestones MOU Contract for Peruvian National Provisional Patent Cactus Publication of LOI signed with Comprehensive agreement chemical and plant Agricultural application Cultivation Mescaline review in the Folium Labs Market Study of a Comprehensive Successfully established Mescaline Research i
Slide 13: Intellectual Property (IP), Licensing & Drug Candidates
Intellectual Property (IP), Licensing & Drug Candidates Key Licensing and Product/Drug Candidates: • Licensing: Initial Study Permit (Peru), 1st SERFOR contract awarded, 2nd anticipated 2024 (H2) • Products: Full spectrum NTe1 (with mescaline), NTe2 (without mescaline) Current IP Portfolio: • Patent
Slide 14: Our Key Advantages
Our Key Advantages: Streamlined Development Path • From Seed to Science: Our development journey is transparent and strictly adheres to ethical and legal standards, seamlessly transitioning from skilled cultivation to extraction, robust drug development, and rigorous clinical trials Drug Development
Slide 15: Leadership Team
Leadership Team Ian Campbell, MSc – Chief Executive Officer and Director – Mr. Campbell is an executive leader who has an international reputation for building effective teams, managing operations and product commercialization. He has managed multinational entities residing in the US, Canada as well
Slide 16: Scientific & Impact Advisory Committee
Scientific & Impact Advisory Committee Professor David Nutt, MD – David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Imperial College London. He was previously President of the European Brain Council, British Association of Psy
Slide 17: Contact Information
Contact Information Ian Campbell, CEO Neural Therapeutics Inc. Tel: 647-697-6875 E: [email protected] 77 King Street West, Suite 2905 Toronto, ON M5K 1H1 18
Slide 18: Appendix
Appendix 19
Slide 19: Neural Therapeutics Philosophy
Neural Therapeutics Philosophy Why we are focusing on mescaline from natural sources, in particular the San Pedro cactus Mescaline is Different Honoring Ethnobotanical Use ❖ Mescaline has a unique receptor drug affinity and response than ❖ Thousands of years of historical experience is an invaluable
Slide 20: Mescaline vs. Other Psychedelics
Mescaline vs. Other Psychedelics Typical Psychedelic Molecular Duration of Hallucinogenic Potential Therapeutic Uses Onset of Effects Substance Structure Effects Dose Addiction (e.g., alcohol), Anxiety LSD 0.05 - 0.2 mg 30 - 40 min 8 - 12h associated with terminal illness Addiction (tobacco, alcohol
Slide 21: Mescaline - A History of Enhanced Safety
Mescaline - A History of Enhanced Safety Potential Psychedelic Psychological Cardiovascular Recorded Therapeutic Substance Effects Risk Deaths Uses Substance Use Disorder, Addiction Treatment Alcohol Use 0 reported - • Ibogaine and Mescaline both have high Disorder, Mescaline Anxiety, Low Very Low 5
Slide 22: About Psychedelic Cacti
About Psychedelic Cacti Indigenous/Native populations have used Peyote and San Pedro as botanical medicines for millennia Contains the highest concentration of Mescaline – around 3 to 6% of Despite the lower mescaline the dried weight concentration at around 1 - 4.5%, San Pedro Cactus the larger mas
Slide 23: Sources – Market Statistics
Sources – Market Statistics Pharmaceutical • ADHD: ADHD Therapeutics Market Size, Trends & Growth | 2021 to 2026 (marketdataforecast.com) • Anti-addiction: Addiction Treatment Market Size is Projected to Reach US$ 11 Billion by 2027 – The Market Publicist • Anxiety: Anxiety Disorders and Depression
Slide 24: Additional Sources
Additional Sources Market Statistics – Nutraceutical • Dietary Fat Uptake Reduction: https://pubmed.ncbi.nlm.nih.gov/25067985 • Diabetic Control Benefits of Cacti: Antidiabetic Effect of Fresh Nopal (Opuntia ficus-indica) in Low-Dose Streptozotocin-Induced Diabetic Rats Fed a High-Fat Diet (hindawi.
Slide 25: Rights of Action For Damages or Rescission
Rights of Action For Damages or Rescission Securities legislation in certain provinces of Canada provides purchasers with rights of rescission or damages, or both, where an offering memorandum or any amendment to it contains a misrepresentation. A “misrepresentation” is an untrue statement of a mat
Neural Therapeutics — Investor Presentation (June 2024) on 6ix